A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care
Phase 3
Completed
- Conditions
- HIV-1
- Interventions
- Drug: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC
- First Posted Date
- 2017-07-24
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 109
- Registration Number
- NCT03227861
- Locations
- ๐บ๐ธ
Spectrum Medical Group, Phoenix, Arizona, United States
๐บ๐ธThe Office of Franco Felizarta, MD, Bakersfield, California, United States
๐บ๐ธJeffrey Goodman Clinic - DBA Los Angeles Gay and Lesbian Center, Los Angeles, California, United States
Multiple Myeloma Patient Registry
Terminated
- Conditions
- Multiple Myeloma
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT03180853
- Locations
- ๐บ๐ธ
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
๐บ๐ธMercy Research, Fort Smith, Arkansas, United States
๐บ๐ธGenesis Cancer Center, Hot Springs, Arkansas, United States
A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment
Completed
- Conditions
- Suicidality
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 130
- Registration Number
- NCT03085108
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham, Birmingham, Alabama, United States
๐บ๐ธCNS Network, Garden Grove, California, United States
๐บ๐ธRutgers University, Piscataway, New Jersey, United States
Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation
Phase 4
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2016-12-19
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 139
- Registration Number
- NCT02996435
Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2016-12-07
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT02984852
A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma
Phase 2
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-10-08
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 101
- Registration Number
- NCT02951819
Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2020-04-15
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1279
- Registration Number
- NCT02728934
Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT02663193
Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)
Completed
- Conditions
- Schizophrenia
- Interventions
- Other: Caregiver psycho-education and skills trainingOther: Caregiver support available at the study site
- First Posted Date
- 2015-11-09
- Last Posted Date
- 2019-01-23
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 296
- Registration Number
- NCT02600741
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
- First Posted Date
- 2015-10-22
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 114
- Registration Number
- NCT02584660